Clinical Trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.
Protocol Amendment History 4 changes
critical Recruitment opened 2026-07-31
notable Trial sites reduced: 60 -> 57 locations 2026-07-31
notable Primary completion moved earlier: 2032-05-20 -> 2028-08-15 2026-07-16
notable Trial sites expanded: 55 -> 58 locations 2026-05-30
Trial Details
NCT Number NCT07492680
Lead Sponsor Bristol-Myers Squibb
Conditions Solid Tumors
Enrollment 260 participants
Start Date 2026-07-27
Primary Completion 2028-08-15 (estimated)
Study Completion 2032-05-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-30